PRMT1 and colorectal carcinoma: Pharmacological inhibition of PRMT1 significantly reduces the ADMA level of NONO and abrogates the malignant phenotype associated with NONO R251 ADMA in both KRAS WT and KRAS mutant CRC cells[93].